Triazole derivatives
    1.
    发明授权
    Triazole derivatives 有权
    三唑衍生物

    公开(公告)号:US08618285B2

    公开(公告)日:2013-12-31

    申请号:US11816465

    申请日:2006-01-25

    CPC分类号: C07D249/12

    摘要: Novel triazole derivatives of the formula (I), in which R1-R6, and Y have the meanings indicated in claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

    摘要翻译: 式(I)的新型三唑衍生物,其中R 1 -R 6和Y具有权利要求1所述的含义,是HSP90抑制剂,可用于制备用于治疗其中抑制,调节 和/或调节HSP90起作用。

    Imidazole derivatives as phosphodiesterase VII inhibitors
    3.
    发明授权
    Imidazole derivatives as phosphodiesterase VII inhibitors 失效
    咪唑衍生物作为磷酸二酯酶VII抑制剂

    公开(公告)号:US07491742B2

    公开(公告)日:2009-02-17

    申请号:US10750878

    申请日:2004-01-05

    IPC分类号: A61K31/415

    CPC分类号: C07D491/04 C07D495/04

    摘要: Imidazole derivatives of the formula I in which R1 is H, A, benzyl, indan-5-yl, 1,2,3,4-tetrahydronaphthalen-5-yl, dibenzothien-2-yl, or phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, A-CO—NH, benzyloxy, alkoxy, COOH or COOA, R2 is H or A, X is O or S, Hal is F, Cl, Br or I, A is alkyl with 1 to 6 C atoms, and the physiologically acceptable salts and/or solvates thereof as phosphodiesterase VII inhibitors and the use thereof for producing a pharmaceutical.

    摘要翻译: 式I的咪唑衍生物,其中R 1是H,A,苄基,茚满-5-基,1,2,3,4-四氢萘-5-基,二苯并噻吩-2-基或未取代或单 - ,Hal,A,A-CO-NH,苄氧基,烷氧基,COOH或COOA二取代或三取代,R 2为H或A,X为O或S,Hal为F,Cl,Br或I, 1至6个C原子,以及其作为磷酸二酯酶VII抑制剂的生理学上可接受的盐和/或溶剂合物及其用于制备药物的用途。

    Hydrazono-malonitriles
    7.
    发明授权
    Hydrazono-malonitriles 失效
    肼类 - 丙二醛

    公开(公告)号:US07544684B2

    公开(公告)日:2009-06-09

    申请号:US11497235

    申请日:2006-08-02

    CPC分类号: C07D403/12 C07D237/04

    摘要: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

    摘要翻译: 其中R 1,R 2,R 3,R 3'和R 4具有权利要求1中给出的含义的式(I)的肼基 - 丙腈衍生物作为磷酸二酯酶IV抑制剂起作用,可用于治疗骨质疏松症,恶病质,恶病质,动脉粥样硬化, 类风湿关节炎,多发性硬化,糖尿病,炎症过程,过敏,哮喘,自身免疫性疾病,心肌疾病和艾滋病。

    Aryl oximes
    8.
    发明授权
    Aryl oximes 失效
    芳肟

    公开(公告)号:US07470687B2

    公开(公告)日:2008-12-30

    申请号:US11429181

    申请日:2006-05-08

    IPC分类号: A61K31/501 A61K31/50

    摘要: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.

    摘要翻译: 式(I)的芳基肟衍生物,其中R 1,R 2,R 3,X和B如权利要求1所定义,作为磷酸二酯酶IV抑制剂,可用于治疗骨质疏松症,肿瘤,恶病质,动脉粥样硬化,类风湿 关节炎,多发性硬化,糖尿病,炎症过程,过敏,哮喘,自身免疫疾病,心肌疾病和艾滋病。